From: Fasting to enhance Cancer treatment in models: the next steps
Period | Model | Cancer type | Cancer prevention | Treatment enhancement | Protective effect | Ref |
---|---|---|---|---|---|---|
Cell lines | ||||||
24 h | BxPC-3, MiaPaca-2 and Panc-1 | Pancreatic | Y | [9] | ||
24 h | SKBR3, BT474, HCT116, HCC827, H3122 | Colorectal, breast | Y | Y | [80] | |
24 h | U251, LN229, and A172 | Glioblastoma | Y | Y | [11] | |
24 h | LN229, SH-SY5Y | Glioma, neuroblastoma | Y | Y | [81] | |
48 h | CT26 | Colon | Y | [10] | ||
Animal | ||||||
72 h | Male BALB/c mice | Colon | Y | [12] | ||
24 h | Female Nu/Nu mice | Pancreatic | Y | [9] | ||
48 h (MC) | Female BALB/c mice | Colon | Y | [10] | ||
72 h | LID mice | Melanoma | Y | Y | [73] | |
48 h (MC) | BALB/c and C57BL/6 mice | Neuroblastoma, breast, ovarian | Y | Y | [6] | |
48 h (MC) | Female BALB/c athymic mice | Colorectal, breast | Y | Y | [80] | |
24–48 h (MC) | Male C57BL/6 N mice | Glioblastoma | Y | Y | [11] | |
24 h | Canine | Lymphoma | Y | [82] |